Shilpa Medicare Ltd - 530549 - Shilpa Medicare Limited Ties Up With Cadila Healthcare Ltd For Production Of Zycov-D Vaccine
This is to inform you that Shilpa Medicare Limited ('SML' or 'the Company'), via its wholly owned subsidiary, Shilpa Biologicals Pvt Ltd (SBPL), has entered into a definitive agreement with Cadila Healthcare Ltd (CHL) for production-supply of the ZyCov-D vaccine drug substance from its integrated Biologics R&D; cum Manufacturing center at Dharwad, Karnataka Shilpa Medicare Ltd - 530549 - BOOK CLOSURE OF SHILPA MEDICARE LIMITED
Wednesday, 22 September 2021 to Monday, 27 September 2021. SHILPA MEDICARE LTD. - 530549 - RECORD DATE, CUT OFF DATE AND BOOK CLOSURE DATE FOR THE PURPOSES OF ANNUAL GENERAL MEETING AND DIVIDEND
RECORD DATE: 21ST SEPTEMBER, 2021 BOOK CLOSURE DATE: 21ST SEPTEMBER, 2021 TO 27TH SEPTEMBER, 2021 CUT OFF DATE FOR E VOTING: 21ST SEPTEMBER, 2021 SHILPA MEDICARE LTD. - 530549 - ANNUAL GENERAL MEETING NOTICE INTIMATION.
SHILPA MEDICARE LIMITED''S ANNUAL GENERAL MEETING TO BE HELD ON 28TH SEPTEMBER, 2021 @ 11:30 AM. SHILPA MEDICARE LTD. - 530549 - Reg. 34 (1) Annual Report
Annual Report of Shilpa Medicare Limited for the FY 2020-21. Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Meeting Updates
APPOINTMENT OF INDEPENDENT DIRECTORS.
Shilpa Medicare Gains On Receiving Nod For COVID-19 Adjunct Therapy Drug
2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients, Shilpa Medicare added. Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg
Shilpa Medicare Limited has received DCG(i) approval for '2-Deoxy-2-Glucose' (Bulk & Oral Powder) SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tano Mauritius India FVCI II Shilpa Medicare Ltd - 530549 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pivotal Enterprises Pvt Ltd